Improving the Breadth of the Host’s Immune Response to Lassa Virus

In 2017, the global Coalition for Epidemic Preparedness (CEPI) declared Lassa virus disease to be one of the world’s foremost biothreats. In January 2018, World Health Organization experts met to address the Lassa biothreat. It was commonly recognized that the diversity of Lassa virus (LASV) isolate...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Pathogens (Basel) Ročník 7; číslo 4; s. 84
Hlavní autoři: Zapata, Juan, Medina-Moreno, Sandra, Guzmán-Cardozo, Camila, Salvato, Maria
Médium: Journal Article
Jazyk:angličtina
Vydáno: Switzerland MDPI AG 28.10.2018
MDPI
Témata:
Antigens
B cell anergy
broadly-neutralizing antibodies
Chemokines
conformational antigens
conserved antigens
cross-restriction
Cytokines
Dendritic cells
Disease
dominant and subdominant epitopes
Ebola virus
Edema
Epidemics
Fc-gamma receptors
focused immunity
Genetic diversity
Hearing loss
Immune response
Immune system
Infections
Influenza
Interferon
Lassa virus disease (LVD)
Medical research
mimicry
Pathogenesis
Pathogens
Public health
Review
vaccine breadth
Vaccines
Viral diseases
Viruses
West Africa
focused immunity
Lassa virus disease (LVD)
conserved antigens
broadly-neutralizing antibodies
vaccine breadth
mimicry
dominant and subdominant epitopes
conformational antigens
cross-restriction
B cell anergy
Fc-gamma receptors
ISSN:2076-0817, 2076-0817
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract In 2017, the global Coalition for Epidemic Preparedness (CEPI) declared Lassa virus disease to be one of the world’s foremost biothreats. In January 2018, World Health Organization experts met to address the Lassa biothreat. It was commonly recognized that the diversity of Lassa virus (LASV) isolated from West African patient samples was far greater than that of the Ebola isolates from the West African epidemic of 2013–2016. Thus, vaccines produced against Lassa virus disease face the added challenge that they must be broadly-protective against a wide variety of LASV. In this review, we discuss what is known about the immune response to Lassa infection. We also discuss the approaches used to make broadly-protective influenza vaccines and how they could be applied to developing broad vaccine coverage against LASV disease. Recent advances in AIDS research are also potentially applicable to the design of broadly-protective medical countermeasures against LASV disease.
AbstractList In 2017, the global Coalition for Epidemic Preparedness (CEPI) declared Lassa virus disease to be one of the world’s foremost biothreats. In January 2018, World Health Organization experts met to address the Lassa biothreat. It was commonly recognized that the diversity of Lassa virus (LASV) isolated from West African patient samples was far greater than that of the Ebola isolates from the West African epidemic of 2013–2016. Thus, vaccines produced against Lassa virus disease face the added challenge that they must be broadly-protective against a wide variety of LASV. In this review, we discuss what is known about the immune response to Lassa infection. We also discuss the approaches used to make broadly-protective influenza vaccines and how they could be applied to developing broad vaccine coverage against LASV disease. Recent advances in AIDS research are also potentially applicable to the design of broadly-protective medical countermeasures against LASV disease.
In 2017, the global Coalition for Epidemic Preparedness (CEPI) declared Lassa virus disease to be one of the world's foremost biothreats. In January 2018, World Health Organization experts met to address the Lassa biothreat. It was commonly recognized that the diversity of Lassa virus (LASV) isolated from West African patient samples was far greater than that of the Ebola isolates from the West African epidemic of 2013⁻2016. Thus, vaccines produced against Lassa virus disease face the added challenge that they must be broadly-protective against a wide variety of LASV. In this review, we discuss what is known about the immune response to Lassa infection. We also discuss the approaches used to make broadly-protective influenza vaccines and how they could be applied to developing broad vaccine coverage against LASV disease. Recent advances in AIDS research are also potentially applicable to the design of broadly-protective medical countermeasures against LASV disease.In 2017, the global Coalition for Epidemic Preparedness (CEPI) declared Lassa virus disease to be one of the world's foremost biothreats. In January 2018, World Health Organization experts met to address the Lassa biothreat. It was commonly recognized that the diversity of Lassa virus (LASV) isolated from West African patient samples was far greater than that of the Ebola isolates from the West African epidemic of 2013⁻2016. Thus, vaccines produced against Lassa virus disease face the added challenge that they must be broadly-protective against a wide variety of LASV. In this review, we discuss what is known about the immune response to Lassa infection. We also discuss the approaches used to make broadly-protective influenza vaccines and how they could be applied to developing broad vaccine coverage against LASV disease. Recent advances in AIDS research are also potentially applicable to the design of broadly-protective medical countermeasures against LASV disease.
In 2017, the global Coalition for Epidemic Preparedness (CEPI) declared Lassa virus disease to be one of the world's foremost biothreats. In January 2018, World Health Organization experts met to address the Lassa biothreat. It was commonly recognized that the diversity of Lassa virus (LASV) isolated from West African patient samples was far greater than that of the Ebola isolates from the West African epidemic of 2013⁻2016. Thus, vaccines produced against Lassa virus disease face the added challenge that they must be broadly-protective against a wide variety of LASV. In this review, we discuss what is known about the immune response to Lassa infection. We also discuss the approaches used to make broadly-protective influenza vaccines and how they could be applied to developing broad vaccine coverage against LASV disease. Recent advances in AIDS research are also potentially applicable to the design of broadly-protective medical countermeasures against LASV disease.
Author Zapata, Juan
Medina-Moreno, Sandra
Salvato, Maria
Guzmán-Cardozo, Camila
AuthorAffiliation Institute of Human Virology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA; smmoreno@ihv.umaryland.edu (S.M.-M.); mcguzmanc13@gmail.com (C.G.-C.); MSalvato@ihv.umaryland.edu (M.S.S.)
AuthorAffiliation_xml – name: Institute of Human Virology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA; smmoreno@ihv.umaryland.edu (S.M.-M.); mcguzmanc13@gmail.com (C.G.-C.); MSalvato@ihv.umaryland.edu (M.S.S.)
Author_xml – sequence: 1
  givenname: Juan
  orcidid: 0000-0003-1931-6147
  surname: Zapata
  fullname: Zapata, Juan
– sequence: 2
  givenname: Sandra
  surname: Medina-Moreno
  fullname: Medina-Moreno, Sandra
– sequence: 3
  givenname: Camila
  orcidid: 0000-0001-7139-2601
  surname: Guzmán-Cardozo
  fullname: Guzmán-Cardozo, Camila
– sequence: 4
  givenname: Maria
  surname: Salvato
  fullname: Salvato, Maria
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30373278$$D View this record in MEDLINE/PubMed
BookMark eNp1ks9u3CAQxlGVqknT3HuqLPXSyzaAwcaXSk36JyutFClqe0UYD7usbHABR-qtr5HXy5MUZ5MoWalcYOCb33wDvEYHzjtA6C3BH8uywaejShu_BhdrzDAW7AU6oriuFliQ-uDJ-hCdxLjFeQg8x6_QYYnLuqS1OEJflsMY_LV16yJtoDgLoLq0Kby5Cy98TLd_b2KxHIbJQXEFcfQuQpF8sVIxquKXDVN8g14a1Uc4uZ-P0c9vX3-cXyxWl9-X559XC815lRaGC9YBkGysUYQp0yhWsuzKiBZzzlhHus5wRetWCSpo1WrdsYa2GlPVGlIeo-WO23m1lWOwgwp_pFdW3m34sJYqJKt7kMqYOlfQmgpglFctbgQB3XTAhSG0zqxPO9Y4tQN0GlwKqn8GfX7i7Eau_bWsSlKyhmfAh3tA8L8niEkONmroe-XAT1HSXIU0uQucpe_3pFs_BZevSlI-d9owNjt699TRo5WHx8qCaifQwccYwEhtk0rWzwZtLwmW88eQ-x8jJ-K9xAf2f1P-Ab0YvjU
CitedBy_id crossref_primary_10_3390_pathogens8030133
crossref_primary_10_3390_pathogens8010009
crossref_primary_10_3390_v13030484
crossref_primary_10_1093_infdis_jiz284
crossref_primary_10_3390_v14091986
crossref_primary_10_12688_f1000research_16989_1
crossref_primary_10_1371_journal_pntd_0011209
crossref_primary_10_3389_fimmu_2019_00372
crossref_primary_10_3390_vaccines7010011
crossref_primary_10_3390_pathogens9060437
crossref_primary_10_1126_scitranslmed_abq0991
crossref_primary_10_3390_vaccines10101668
Cites_doi 10.1128/JVI.77.3.1727-1737.2003
10.1016/S0140-6736(79)90659-7
10.1016/S0140-6736(87)90767-7
10.1371/journal.pone.0123249
10.1007/s11262-006-0050-3
10.1128/JVI.75.23.11677-11685.2001
10.1093/infdis/155.3.437
10.1093/infdis/jiy159
10.1128/JVI.01024-18
10.1128/JVI.01948-08
10.1007/BF02122441
10.1128/JVI.02230-17
10.1016/0035-9203(77)90085-2
10.1016/j.virol.2003.12.013
10.1016/j.virol.2012.02.001
10.1128/JVI.79.22.13934-13942.2005
10.1128/JVI.02876-06
10.1038/nsmb.3291
10.1001/jama.1990.03450160063030
10.1016/j.vaccine.2008.03.078
10.1016/j.coviro.2018.05.002
10.4269/ajtmh.1970.19.677
10.1038/ncomms11544
10.1080/21645515.2017.1356500
10.1186/1743-422X-8-81
10.1128/JVI.02256-17
10.1126/science.8248784
10.1128/CVI.00028-17
10.1186/1743-422X-10-52
10.1002/jmv.1890400308
10.1016/j.cell.2015.07.020
10.1016/j.virol.2006.01.026
10.1002/rmv.329
10.1128/JVI.00882-07
10.1093/infdis/146.3.360
10.1128/jvi.71.3.2292-2302.1997
10.1016/0042-6822(92)90514-P
10.4269/ajtmh.1985.34.999
10.1128/JVI.01613-17
10.1002/jmv.1890260204
10.1016/j.vaccine.2008.07.057
10.1016/j.vaccine.2011.12.134
10.1093/infdis/155.3.456
10.1371/journal.pmed.0020183
10.1016/0035-9203(85)90388-8
10.1172/JCI200422374
10.1186/1743-422X-8-478
10.3390/pathogens8030133
10.1371/journal.pone.0122839
10.1128/JVI.01883-17
10.1128/JVI.06508-11
10.1146/annurev-med-052912-123749
10.1261/rna.2238705
10.1016/j.virol.2005.12.001
10.1002/(SICI)1096-9071(199912)59:4<552::AID-JMV21>3.0.CO;2-A
10.1186/1743-422X-8-314
10.1007/s00705-004-0385-9
10.3390/molecules22111837
10.1128/JVI.79.4.2461-2473.2005
10.1261/rna.060137.116
10.1007/s00705-018-3843-5
10.1128/JVI.02120-10
10.1056/NEJMoa1804498
10.1093/infdis/155.3.465
10.1371/journal.pntd.0000388
10.1128/jvi.13.1.171-180.1974
10.1038/nm.4396
10.1016/j.antiviral.2007.11.003
10.3389/fimmu.2018.00598
10.1172/JCI25608
10.4049/jimmunol.172.5.2861
10.1128/JVI.00536-07
10.1186/1743-422X-8-205
10.1586/14760584.3.2.189
10.1016/j.vaccine.2007.02.038
10.1084/jem.179.2.425
10.1073/pnas.1613225113
10.1016/j.vaccine.2010.11.079
10.1016/S1286-4579(01)01508-8
10.1016/0035-9203(72)90268-4
10.4049/jimmunol.170.6.2797
10.1016/j.vaccine.2016.06.071
10.1038/nature09605
10.1056/NEJM198601023140104
10.1371/journal.pone.0117242
10.1128/JVI.00763-09
10.4049/jimmunol.1700953
10.1371/journal.pntd.0003736
10.1371/journal.ppat.1005276
10.1073/pnas.1016404108
10.1093/gbe/evy050
10.1128/JVI.00155-10
10.1016/j.virol.2010.11.023
10.1136/bmj.327.7426.1271
10.1128/JVI.74.15.6992-7004.2000
10.1111/j.1365-2141.1989.tb04321.x
10.1016/j.virol.2015.02.017
10.1093/clinids/11.Supplement_4.S743
10.1126/science.aao3859
10.1038/s41467-018-06741-w
10.1016/j.vaccine.2018.06.048
10.1371/journal.pmed.1002066
10.1126/science.1254990
10.1093/infdis/jix201
10.1002/jmv.1890370102
10.4269/ajtmh.1988.38.407
10.4269/ajtmh.1986.35.401
10.1007/BF00172063
10.1128/JVI.03349-14
10.1128/JVI.74.5.2186-2192.2000
10.1038/31514
10.1006/viro.1996.0259
10.1038/nature13601
10.1128/JVI.00555-06
10.1128/JVI.78.6.3162-3169.2004
ContentType Journal Article
Copyright 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2018 by the authors. 2018
Copyright_xml – notice: 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2018 by the authors. 2018
DBID AAYXX
CITATION
NPM
7T7
8FD
8FE
8FH
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
C1K
CCPQU
DWQXO
FR3
GNUQQ
HCIFZ
LK8
M7P
P64
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.3390/pathogens7040084
DatabaseName CrossRef
PubMed
Industrial and Applied Microbiology Abstracts (Microbiology A)
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
Biological Science Collection
ProQuest Central
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Central Korea
Engineering Research Database
ProQuest Central Student
SciTech Premium Collection
Biological Sciences
Biological Science Database
Biotechnology and BioEngineering Abstracts
Proquest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest Central Student
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest Central
ProQuest One Applied & Life Sciences
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (New)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
Biological Science Database
ProQuest SciTech Collection
Biotechnology and BioEngineering Abstracts
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database
MEDLINE - Academic


PubMed
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: PIMPY
  name: Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
Public Health
EISSN 2076-0817
ExternalDocumentID oai_doaj_org_article_aff74afcc28e4256b0981ec9de58f127
PMC6313495
30373278
10_3390_pathogens7040084
Genre Journal Article
Review
GeographicLocations West Africa
GeographicLocations_xml – name: West Africa
GrantInformation_xml – fundername: EU Commission Horizon2020 STARBIOS2
  grantid: 709517
– fundername: NIH HHS
  grantid: R01 AI052367, R01 AI068961, 5RC2CA149001,R21-AI074790
GroupedDBID 53G
5VS
8FE
8FH
AADQD
AAHBH
AAYXX
ADBBV
ADRAZ
AFFHD
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
CCPQU
CITATION
DIK
GROUPED_DOAJ
HCIFZ
HYE
IPNFZ
KQ8
LK8
M48
M7P
MODMG
M~E
OK1
PGMZT
PHGZM
PHGZT
PIMPY
PQGLB
PROAC
RIG
RPM
NPM
7T7
8FD
ABUWG
AZQEC
C1K
DWQXO
FR3
GNUQQ
P64
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c556t-f584dee10769a14af9a434080f8b05544d1ddf5a27ba82826bccd492bc02abf13
IEDL.DBID M7P
ISICitedReferencesCount 12
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000454525400009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2076-0817
IngestDate Fri Oct 03 12:40:39 EDT 2025
Tue Nov 04 02:03:06 EST 2025
Sun Nov 09 10:05:19 EST 2025
Fri Jul 25 09:31:59 EDT 2025
Thu Jan 02 23:04:24 EST 2025
Sat Nov 29 07:17:08 EST 2025
Tue Nov 18 21:47:39 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords focused immunity
Lassa virus disease (LVD)
conserved antigens
broadly-neutralizing antibodies
vaccine breadth
mimicry
dominant and subdominant epitopes
conformational antigens
cross-restriction
B cell anergy
Fc-gamma receptors
Language English
License Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c556t-f584dee10769a14af9a434080f8b05544d1ddf5a27ba82826bccd492bc02abf13
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0001-7139-2601
0000-0003-1931-6147
OpenAccessLink https://www.proquest.com/docview/2582829447?pq-origsite=%requestingapplication%
PMID 30373278
PQID 2582829447
PQPubID 2032351
ParticipantIDs doaj_primary_oai_doaj_org_article_aff74afcc28e4256b0981ec9de58f127
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6313495
proquest_miscellaneous_2127198260
proquest_journals_2582829447
pubmed_primary_30373278
crossref_citationtrail_10_3390_pathogens7040084
crossref_primary_10_3390_pathogens7040084
PublicationCentury 2000
PublicationDate 20181028
PublicationDateYYYYMMDD 2018-10-28
PublicationDate_xml – month: 10
  year: 2018
  text: 20181028
  day: 28
PublicationDecade 2010
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Pathogens (Basel)
PublicationTitleAlternate Pathogens
PublicationYear 2018
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Peters (ref_36) 1989; 11
ref_93
ref_13
Meulen (ref_73) 2004; 321
Maes (ref_80) 2018; 163
Jiang (ref_85) 2011; 29
Weidmann (ref_8) 2011; 8
Goicochea (ref_75) 2012; 30
McCormick (ref_41) 2002; 262
Mahanty (ref_42) 2003; 170
Branco (ref_47) 2011; 8
McCormick (ref_67) 1986; 314
Cooke (ref_99) 1994; 179
Lukashevich (ref_10) 1999; 59
Lukashevich (ref_62) 1993; 40
Hensley (ref_40) 2011; 8
Bachmann (ref_102) 1993; 262
Haynes (ref_94) 2014; 344
ref_121
An (ref_114) 1997; 71
Cummins (ref_28) 1989; 72
Tomori (ref_63) 1988; 38
ref_27
McCormick (ref_30) 1987; 134
Zuniga (ref_51) 2006; 80
McCormick (ref_65) 2001; 11
Arnold (ref_61) 1977; 71
Carrion (ref_16) 2007; 25
Bowen (ref_5) 2000; 74
Carnec (ref_86) 2018; 92
Hagen (ref_113) 2018; 9
Kentsis (ref_122) 2005; 11
McCormick (ref_64) 1987; 155
Hastie (ref_69) 2018; 31
Wyatt (ref_96) 1998; 393
Badusche (ref_72) 2000; 74
Leifer (ref_66) 1970; 19
Pushko (ref_77) 2001; 75
Huang (ref_111) 2014; 515
Carrion (ref_25) 2007; 81
Jahrling (ref_76) 1986; 175
Strand (ref_106) 1974; 13
Baize (ref_11) 2004; 172
Cashman (ref_88) 2017; 13
Lukashevich (ref_15) 2005; 79
Schmitz (ref_22) 2002; 4
Forni (ref_55) 2018; 10
Richmond (ref_71) 2003; 327
Lange (ref_32) 1985; 34
Gristick (ref_97) 2016; 23
Burnett (ref_98) 2018; 360
McCormick (ref_60) 1992; 37
ref_81
Clarke (ref_90) 2016; 34
Hastie (ref_49) 2011; 108
Hayes (ref_58) 2012; 86
McCormick (ref_70) 2004; 3
ref_89
Liu (ref_120) 2006; 116
Cummins (ref_33) 1990; 264
ref_87
Xing (ref_54) 2015; 89
Ping (ref_101) 2018; 36
Giannakas (ref_50) 2007; 81
Provine (ref_109) 2012; 427
Emonet (ref_48) 2009; 83
Ilyinskii (ref_103) 2008; 26
Oldstone (ref_21) 2011; 411
Lukashevich (ref_14) 1992; 188
Mukhopadhyay (ref_119) 2017; 199
Johnson (ref_20) 1987; 155
Kim (ref_91) 2015; 66
Andersen (ref_6) 2015; 162
Cohen (ref_110) 2018; 92
Shubin (ref_107) 2017; 24
McCormick (ref_29) 1988; 26
Peters (ref_83) 1987; 134
Lukashevich (ref_18) 2008; 26
Kell (ref_44) 2015; 479–480
Djavani (ref_92) 2005; 79
McCormick (ref_24) 1986; 35
Solbrig (ref_37) 1991; 31
Asper (ref_45) 2004; 78
Mire (ref_68) 2017; 23
McElroy (ref_74) 2017; 215
Snapper (ref_105) 2018; 9
Pinschewer (ref_95) 2004; 114
Khan (ref_35) 2008; 78
Iwasaki (ref_124) 2018; 92
Hickerson (ref_125) 2018; 218
Kiley (ref_78) 1979; 2
Emonet (ref_9) 2006; 350
Clegg (ref_82) 1987; 2
Moshkoff (ref_17) 2007; 34
Qi (ref_52) 2010; 468
ref_115
ref_117
Volpon (ref_123) 2017; 23
ref_118
Grove (ref_56) 2011; 8
Haijema (ref_104) 2013; 4
Jahrling (ref_23) 1985; 79
Edington (ref_39) 1972; 66
Leon (ref_112) 2016; 113
Jacobs (ref_43) 1996; 219
Baize (ref_38) 2009; 83
Fedeli (ref_26) 2018; 92
Lukashevich (ref_59) 2004; 149
Zhou (ref_53) 2010; 84
Rammensee (ref_116) 1995; 41
Bredenbeek (ref_84) 2006; 345
Lukashevich (ref_46) 2003; 77
Robinson (ref_108) 2016; 7
Mitchell (ref_34) 1987; 155
ref_100
Djavani (ref_57) 2007; 81
ref_1
Pannetier (ref_12) 2011; 85
ref_3
ref_2
Walker (ref_79) 1982; 146
Knobloch (ref_31) 1980; 31
Zapata (ref_19) 2013; 10
ref_4
ref_7
References_xml – volume: 77
  start-page: 1727
  year: 2003
  ident: ref_46
  article-title: Arenavirus-mediated liver pathology: Acute lymphocytic choriomeningitis virus infection of rhesus macaques is characterized by high-level interleukin-6 expression and hepatocyte proliferation
  publication-title: J. Virol.
  doi: 10.1128/JVI.77.3.1727-1737.2003
– volume: 2
  start-page: 738
  year: 1979
  ident: ref_78
  article-title: Protection of rhesus monkeys from lassa virus by immunisation with closely related arenavirus
  publication-title: Lancet
  doi: 10.1016/S0140-6736(79)90659-7
– volume: 2
  start-page: 186
  year: 1987
  ident: ref_82
  article-title: Vaccinia recombinant expressing lassa-virus internal nucleocapsid protein protects guineapigs against lassa fever
  publication-title: Lancet
  doi: 10.1016/S0140-6736(87)90767-7
– ident: ref_117
  doi: 10.1371/journal.pone.0123249
– volume: 34
  start-page: 169
  year: 2007
  ident: ref_17
  article-title: Molecular characterization of a reassortant virus derived from lassa and mopeia viruses
  publication-title: Virus Genes
  doi: 10.1007/s11262-006-0050-3
– volume: 75
  start-page: 11677
  year: 2001
  ident: ref_77
  article-title: Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with lassa and ebola viruses
  publication-title: J. Virol.
  doi: 10.1128/JVI.75.23.11677-11685.2001
– volume: 155
  start-page: 437
  year: 1987
  ident: ref_64
  article-title: A prospective study of the epidemiology and ecology of lassa fever
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/155.3.437
– volume: 218
  start-page: 522
  year: 2018
  ident: ref_125
  article-title: Effective treatment of experimental lymphocytic choriomeningitis virus infection: Consideration of favipiravir for use with infected organ transplant recipients
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/jiy159
– ident: ref_100
  doi: 10.1128/JVI.01024-18
– volume: 83
  start-page: 5890
  year: 2009
  ident: ref_38
  article-title: Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys
  publication-title: J. Virol.
  doi: 10.1128/JVI.01948-08
– volume: 175
  start-page: 165
  year: 1986
  ident: ref_76
  article-title: Serology and virulence diversity among old-world arenaviruses, and the relevance to vaccine development
  publication-title: Med. Microbiol. Immunol.
  doi: 10.1007/BF02122441
– volume: 92
  start-page: e02230-17
  year: 2018
  ident: ref_86
  article-title: A vaccine platform against arenaviruses based on a recombinant hyperattenuated mopeia virus expressing heterologous glycoproteins
  publication-title: J. Virol.
  doi: 10.1128/JVI.02230-17
– volume: 71
  start-page: 152
  year: 1977
  ident: ref_61
  article-title: A neutralization test survey for lassa fever activity in lassa, nigeria
  publication-title: Trans. R. Soc. Trop. Med. Hyg.
  doi: 10.1016/0035-9203(77)90085-2
– volume: 321
  start-page: 134
  year: 2004
  ident: ref_73
  article-title: Old and new world arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by lassa virus-specific human cd4+ t-cell clones
  publication-title: Virology
  doi: 10.1016/j.virol.2003.12.013
– volume: 134
  start-page: 5
  year: 1987
  ident: ref_83
  article-title: Experimental studies of arenaviral hemorrhagic fevers
  publication-title: Curr. Top. Microbiol. Immunol.
– volume: 427
  start-page: 25
  year: 2012
  ident: ref_109
  article-title: The neutralization sensitivity of viruses representing human immunodeficiency virus type 1 variants of diverse subtypes from early in infection is dependent on producer cell, as well as characteristics of the specific antibody and envelope variant
  publication-title: Virology
  doi: 10.1016/j.virol.2012.02.001
– volume: 79
  start-page: 13934
  year: 2005
  ident: ref_15
  article-title: A live attenuated vaccine for lassa fever made by reassortment of lassa and mopeia viruses
  publication-title: J. Virol.
  doi: 10.1128/JVI.79.22.13934-13942.2005
– volume: 81
  start-page: 6482
  year: 2007
  ident: ref_25
  article-title: Lassa virus infection in experimentally infected marmosets: Liver pathology and immunophenotypic alterations in target tissues
  publication-title: J. Virol.
  doi: 10.1128/JVI.02876-06
– volume: 23
  start-page: 906
  year: 2016
  ident: ref_97
  article-title: Natively glycosylated hiv-1 env structure reveals new mode for antibody recognition of the cd4-binding site
  publication-title: Nat. Struct. Mol. Biol.
  doi: 10.1038/nsmb.3291
– ident: ref_4
– volume: 264
  start-page: 2093
  year: 1990
  ident: ref_33
  article-title: Acute sensorineural deafness in lassa fever
  publication-title: JAMA
  doi: 10.1001/jama.1990.03450160063030
– volume: 26
  start-page: 3223
  year: 2008
  ident: ref_103
  article-title: Adjuvant potential of aggregate-forming polyglutamine domains
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2008.03.078
– volume: 31
  start-page: 52
  year: 2018
  ident: ref_69
  article-title: Lassa virus glycoprotein: Stopping a moving target
  publication-title: Curr. Opin. Virol.
  doi: 10.1016/j.coviro.2018.05.002
– volume: 19
  start-page: 677
  year: 1970
  ident: ref_66
  article-title: Lassa fever, a new virus disease of man from west africa. Ii. Report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease
  publication-title: Am. J. Trop. Med. Hyg.
  doi: 10.4269/ajtmh.1970.19.677
– volume: 7
  start-page: 11544
  year: 2016
  ident: ref_108
  article-title: Most neutralizing human monoclonal antibodies target novel epitopes requiring both lassa virus glycoprotein subunits
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms11544
– volume: 13
  start-page: 2902
  year: 2017
  ident: ref_88
  article-title: A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against lassa fever
  publication-title: Hum. Vaccin. Immunother.
  doi: 10.1080/21645515.2017.1356500
– volume: 8
  start-page: 81
  year: 2011
  ident: ref_8
  article-title: Quantitative analysis of particles, genomes and infectious particles in supernatants of haemorrhagic fever virus cell cultures
  publication-title: Virol. J.
  doi: 10.1186/1743-422X-8-81
– volume: 92
  start-page: 02256-17
  year: 2018
  ident: ref_124
  article-title: A highly conserved leucine in mammarenavirus matrix z protein is required for z interaction with the virus l polymerase and z stability in cells harboring an active viral ribonucleoprotein
  publication-title: J. Virol.
  doi: 10.1128/JVI.02256-17
– volume: 262
  start-page: 1448
  year: 1993
  ident: ref_102
  article-title: The influence of antigen organization on b cell responsiveness
  publication-title: Science
  doi: 10.1126/science.8248784
– volume: 24
  start-page: 00028-17
  year: 2017
  ident: ref_107
  article-title: An hiv envelope gp120-fc fusion protein elicits effector antibody responses in rhesus macaques
  publication-title: Clin. Vaccine Immunol.
  doi: 10.1128/CVI.00028-17
– volume: 10
  start-page: 52
  year: 2013
  ident: ref_19
  article-title: An attenuated lassa vaccine in siv-infected rhesus macaques does not persist or cause arenavirus disease but does elicit lassa virus-specific immunity
  publication-title: Virol. J.
  doi: 10.1186/1743-422X-10-52
– volume: 40
  start-page: 210
  year: 1993
  ident: ref_62
  article-title: Lassa virus activity in guinea: Distribution of human antiviral antibody defined using enzyme-linked immunosorbent assay with recombinant antigen
  publication-title: J. Med. Virol.
  doi: 10.1002/jmv.1890400308
– volume: 162
  start-page: 738
  year: 2015
  ident: ref_6
  article-title: Clinical sequencing uncovers origins and evolution of lassa virus
  publication-title: Cell
  doi: 10.1016/j.cell.2015.07.020
– volume: 350
  start-page: 251
  year: 2006
  ident: ref_9
  article-title: Phylogeny and evolution of old world arenaviruses
  publication-title: Virology
  doi: 10.1016/j.virol.2006.01.026
– volume: 262
  start-page: 75
  year: 2002
  ident: ref_41
  article-title: Lassa fever
  publication-title: Curr. Top. Microbiol. Immunol.
– volume: 11
  start-page: 331
  year: 2001
  ident: ref_65
  article-title: Towards a human lassa fever vaccine
  publication-title: Rev. Med. Virol.
  doi: 10.1002/rmv.329
– volume: 81
  start-page: 12696
  year: 2007
  ident: ref_50
  article-title: Differential inhibition of type i interferon induction by arenavirus nucleoproteins
  publication-title: J. Virol.
  doi: 10.1128/JVI.00882-07
– volume: 146
  start-page: 360
  year: 1982
  ident: ref_79
  article-title: Experimental infection of rhesus monkeys with lassa virus and a closely related arenavirus, mozambique virus
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/146.3.360
– volume: 71
  start-page: 2292
  year: 1997
  ident: ref_114
  article-title: A multivalent minigene vaccine, containing b-cell, cytotoxic t-lymphocyte, and th epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen
  publication-title: J. Virol.
  doi: 10.1128/jvi.71.3.2292-2302.1997
– ident: ref_3
– volume: 188
  start-page: 600
  year: 1992
  ident: ref_14
  article-title: Generation of reassortants between african arenaviruses
  publication-title: Virology
  doi: 10.1016/0042-6822(92)90514-P
– volume: 34
  start-page: 999
  year: 1985
  ident: ref_32
  article-title: Kinetic study of platelets and fibrinogen in lassa virus-infected monkeys and early pathologic events in mopeia virus-infected monkeys
  publication-title: Am. J. Trop. Med. Hyg.
  doi: 10.4269/ajtmh.1985.34.999
– volume: 92
  start-page: e01613-17
  year: 2018
  ident: ref_26
  article-title: Axl can serve as entry factor for lassa virus depending on the functional glycosylation of dystroglycan
  publication-title: J. Virol.
  doi: 10.1128/JVI.01613-17
– volume: 26
  start-page: 127
  year: 1988
  ident: ref_29
  article-title: Hematologic dysfunction in lassa fever
  publication-title: J. Med. Virol.
  doi: 10.1002/jmv.1890260204
– volume: 26
  start-page: 5246
  year: 2008
  ident: ref_18
  article-title: Safety, immunogenicity, and efficacy of the ml29 reassortant vaccine for lassa fever in small non-human primates
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2008.07.057
– volume: 30
  start-page: 1445
  year: 2012
  ident: ref_75
  article-title: Evaluation of lassa virus vaccine immunogenicity in a cba/j-ml29 mouse model
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2011.12.134
– volume: 155
  start-page: 456
  year: 1987
  ident: ref_20
  article-title: Clinical virology of lassa fever in hospitalized patients
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/155.3.456
– ident: ref_89
  doi: 10.1371/journal.pmed.0020183
– volume: 79
  start-page: 380
  year: 1985
  ident: ref_23
  article-title: Endemic lassa fever in liberia. Iv. Selection of optimally effective plasma for treatment by passive immunization
  publication-title: Trans. R. Soc. Trop. Med. Hyg.
  doi: 10.1016/0035-9203(85)90388-8
– volume: 114
  start-page: 988
  year: 2004
  ident: ref_95
  article-title: Kinetics of protective antibodies are determined by the viral surface antigen
  publication-title: J. Clin. Investig.
  doi: 10.1172/JCI200422374
– volume: 8
  start-page: 478
  year: 2011
  ident: ref_47
  article-title: Emerging trends in lassa fever: Redefining the role of immunoglobulin m and inflammation in diagnosing acute infection
  publication-title: Virol. J.
  doi: 10.1186/1743-422X-8-478
– ident: ref_87
  doi: 10.3390/pathogens8030133
– ident: ref_27
  doi: 10.1371/journal.pone.0122839
– volume: 92
  start-page: e01883-17
  year: 2018
  ident: ref_110
  article-title: Neutralizing activity of broadly neutralizing anti-hiv-1 antibodies against clade b clinical isolates produced in peripheral blood mononuclear cells
  publication-title: J. Virol.
  doi: 10.1128/JVI.01883-17
– volume: 86
  start-page: 7216
  year: 2012
  ident: ref_58
  article-title: Pathogenic old world arenaviruses inhibit tlr2/mal-dependent proinflammatory cytokines in vitro
  publication-title: J. Virol.
  doi: 10.1128/JVI.06508-11
– volume: 66
  start-page: 423
  year: 2015
  ident: ref_91
  article-title: Lessons from the rv144 thai phase iii hiv-1 vaccine trial and the search for correlates of protection
  publication-title: Annu. Rev. Med.
  doi: 10.1146/annurev-med-052912-123749
– volume: 11
  start-page: 1762
  year: 2005
  ident: ref_122
  article-title: Further evidence that ribavirin interacts with eif4e
  publication-title: RNA
  doi: 10.1261/rna.2238705
– volume: 345
  start-page: 299
  year: 2006
  ident: ref_84
  article-title: A recombinant yellow fever 17d vaccine expressing lassa virus glycoproteins
  publication-title: Virology
  doi: 10.1016/j.virol.2005.12.001
– volume: 59
  start-page: 552
  year: 1999
  ident: ref_10
  article-title: Lassa and mopeia virus replication in human monocytes/macrophages and in endothelial cells: Different effects on il-8 and tnf-alpha gene expression
  publication-title: J. Med. Virol.
  doi: 10.1002/(SICI)1096-9071(199912)59:4<552::AID-JMV21>3.0.CO;2-A
– volume: 8
  start-page: 314
  year: 2011
  ident: ref_56
  article-title: Capacity building permitting comprehensive monitoring of a severe case of lassa hemorrhagic fever in sierra leone with a positive outcome: Case report
  publication-title: Virol. J.
  doi: 10.1186/1743-422X-8-314
– volume: 149
  start-page: 2319
  year: 2004
  ident: ref_59
  article-title: Lcmv-mediated hepatitis in rhesus macaques: We but not arm strain activates hepatocytes and induces liver regeneration
  publication-title: Arch. Virol.
  doi: 10.1007/s00705-004-0385-9
– ident: ref_118
  doi: 10.3390/molecules22111837
– volume: 79
  start-page: 2461
  year: 2005
  ident: ref_92
  article-title: The proline-rich homeodomain (prh/hex) protein is down-regulated in liver during infection with lymphocytic choriomeningitis virus
  publication-title: J. Virol.
  doi: 10.1128/JVI.79.4.2461-2473.2005
– volume: 23
  start-page: 927
  year: 2017
  ident: ref_123
  article-title: A biochemical framework for eif4e-dependent mrna export and nuclear recycling of the export machinery
  publication-title: RNA
  doi: 10.1261/rna.060137.116
– volume: 4
  start-page: 282
  year: 2013
  ident: ref_104
  article-title: Bacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applications
  publication-title: Front. Immunol.
– volume: 163
  start-page: 2295
  year: 2018
  ident: ref_80
  article-title: Taxonomy of the family arenaviridae and the order bunyavirales: Update 2018
  publication-title: Arch. Virol.
  doi: 10.1007/s00705-018-3843-5
– volume: 85
  start-page: 8293
  year: 2011
  ident: ref_12
  article-title: Human dendritic cells infected with the nonpathogenic mopeia virus induce stronger t-cell responses than those infected with lassa virus
  publication-title: J. Virol.
  doi: 10.1128/JVI.02120-10
– ident: ref_7
  doi: 10.1056/NEJMoa1804498
– volume: 155
  start-page: 465
  year: 1987
  ident: ref_34
  article-title: Physiological and immunologic disturbances associated with shock in a primate model of lassa fever
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/155.3.465
– ident: ref_1
  doi: 10.1371/journal.pntd.0000388
– volume: 31
  start-page: 419
  year: 1991
  ident: ref_37
  article-title: Headache syndromes in sierra leone, west africa
  publication-title: Headache
– volume: 13
  start-page: 171
  year: 1974
  ident: ref_106
  article-title: Structural proteins of mammalian oncogenic rna viruses: Multiple antigenic determinants of the major internal protein and envelope glycoprotein
  publication-title: J. Virol.
  doi: 10.1128/jvi.13.1.171-180.1974
– volume: 23
  start-page: 1146
  year: 2017
  ident: ref_68
  article-title: Human-monoclonal-antibody therapy protects nonhuman primates against advanced lassa fever
  publication-title: Nat. Med.
  doi: 10.1038/nm.4396
– volume: 78
  start-page: 103
  year: 2008
  ident: ref_35
  article-title: New opportunities for field research on the pathogenesis and treatment of lassa fever
  publication-title: Antivir. Res.
  doi: 10.1016/j.antiviral.2007.11.003
– volume: 9
  start-page: 598
  year: 2018
  ident: ref_105
  article-title: Distinct immunologic properties of soluble versus particulate antigens
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2018.00598
– volume: 116
  start-page: 465
  year: 2006
  ident: ref_120
  article-title: Peptide vaccination of mice immune to lcmv or vaccinia virus causes serious cd8 t cell-mediated, tnf-dependent immunopathology
  publication-title: J. C. Investig.
  doi: 10.1172/JCI25608
– volume: 172
  start-page: 2861
  year: 2004
  ident: ref_11
  article-title: Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.172.5.2861
– volume: 81
  start-page: 7960
  year: 2007
  ident: ref_57
  article-title: Early blood profiles of virus infection in a monkey model for lassa fever
  publication-title: J. Virol.
  doi: 10.1128/JVI.00536-07
– volume: 8
  start-page: 205
  year: 2011
  ident: ref_40
  article-title: Pathogenesis of lassa fever in cynomolgus macaques
  publication-title: Virol. J.
  doi: 10.1186/1743-422X-8-205
– volume: 3
  start-page: 189
  year: 2004
  ident: ref_70
  article-title: Lassa fever vaccine
  publication-title: Expert Rev. Vaccines
  doi: 10.1586/14760584.3.2.189
– volume: 25
  start-page: 4093
  year: 2007
  ident: ref_16
  article-title: A ml29 reassortant virus protects guinea pigs against a distantly related nigerian strain of lassa virus and can provide sterilizing immunity
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2007.02.038
– volume: 179
  start-page: 425
  year: 1994
  ident: ref_99
  article-title: Immunoglobulin signal transduction guides the specificity of b cell-t cell interactions and is blocked in tolerant self-reactive b cells
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.179.2.425
– volume: 113
  start-page: E5944
  year: 2016
  ident: ref_112
  article-title: Optimal activation of fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.1613225113
– volume: 29
  start-page: 1248
  year: 2011
  ident: ref_85
  article-title: Yellow fever 17d-vectored vaccines expressing lassa virus gp1 and gp2 glycoproteins provide protection against fatal disease in guinea pigs
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2010.11.079
– volume: 4
  start-page: 43
  year: 2002
  ident: ref_22
  article-title: Monitoring of clinical and laboratory data in two cases of imported lassa fever
  publication-title: Microbes Infect.
  doi: 10.1016/S1286-4579(01)01508-8
– volume: 66
  start-page: 381
  year: 1972
  ident: ref_39
  article-title: The pathology of lassa fever
  publication-title: Trans. R. Soc. Trop. Med. Hyg.
  doi: 10.1016/0035-9203(72)90268-4
– volume: 170
  start-page: 2797
  year: 2003
  ident: ref_42
  article-title: Cutting edge: Impairment of dendritic cells and adaptive immunity by ebola and lassa viruses
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.170.6.2797
– volume: 34
  start-page: 6597
  year: 2016
  ident: ref_90
  article-title: Live virus vaccines based on a vesicular stomatitis virus (vsv) backbone: Standardized template with key considerations for a risk/benefit assessment
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2016.06.071
– volume: 468
  start-page: 779
  year: 2010
  ident: ref_52
  article-title: Cap binding and immune evasion revealed by lassa nucleoprotein structure
  publication-title: Nature
  doi: 10.1038/nature09605
– volume: 31
  start-page: 389
  year: 1980
  ident: ref_31
  article-title: Clinical observations in 42 patients with lassa fever
  publication-title: Tropenmed. Parasitol.
– volume: 314
  start-page: 20
  year: 1986
  ident: ref_67
  article-title: Lassa fever. Effective therapy with ribavirin
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJM198601023140104
– ident: ref_115
  doi: 10.1371/journal.pone.0117242
– volume: 83
  start-page: 11330
  year: 2009
  ident: ref_48
  article-title: Identification of amino acid residues critical for the anti-interferon activity of the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus
  publication-title: J. Virol.
  doi: 10.1128/JVI.00763-09
– volume: 199
  start-page: 3437
  year: 2017
  ident: ref_119
  article-title: DNA vaccination by electroporation amplifies broadly cross-restricted public tcr clonotypes shared with hiv controllers
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1700953
– ident: ref_93
– ident: ref_81
  doi: 10.1371/journal.pntd.0003736
– ident: ref_13
  doi: 10.1371/journal.ppat.1005276
– volume: 108
  start-page: 2396
  year: 2011
  ident: ref_49
  article-title: Structure of the lassa virus nucleoprotein reveals a dsrna-specific 3′ to 5′ exonuclease activity essential for immune suppression
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.1016404108
– volume: 10
  start-page: 863
  year: 2018
  ident: ref_55
  article-title: Ancient evolution of mammarenaviruses: Adaptation via changes in the l protein and no evidence for host-virus codivergence
  publication-title: Genome Biol. Evol.
  doi: 10.1093/gbe/evy050
– volume: 84
  start-page: 9452
  year: 2010
  ident: ref_53
  article-title: Induction and inhibition of type i interferon responses by distinct components of lymphocytic choriomeningitis virus
  publication-title: J. Virol.
  doi: 10.1128/JVI.00155-10
– volume: 411
  start-page: 170
  year: 2011
  ident: ref_21
  article-title: Decoding arenavirus pathogenesis: Essential roles for alpha-dystroglycan-virus interactions and the immune response
  publication-title: Virology
  doi: 10.1016/j.virol.2010.11.023
– volume: 327
  start-page: 1271
  year: 2003
  ident: ref_71
  article-title: Lassa fever: Epidemiology, clinical features, and social consequences
  publication-title: Br. Med. J.
  doi: 10.1136/bmj.327.7426.1271
– volume: 74
  start-page: 6992
  year: 2000
  ident: ref_5
  article-title: Genetic diversity among lassa virus strains
  publication-title: J. Virol.
  doi: 10.1128/JVI.74.15.6992-7004.2000
– volume: 72
  start-page: 543
  year: 1989
  ident: ref_28
  article-title: A plasma inhibitor of platelet aggregation in patients with lassa fever
  publication-title: Br. J. Haematol.
  doi: 10.1111/j.1365-2141.1989.tb04321.x
– volume: 479–480
  start-page: 110
  year: 2015
  ident: ref_44
  article-title: Rig-i in rna virus recognition
  publication-title: Virology
  doi: 10.1016/j.virol.2015.02.017
– volume: 11
  start-page: S743
  year: 1989
  ident: ref_36
  article-title: Pathogenesis of viral hemorrhagic fevers: Rift valley fever and lassa fever contrasted
  publication-title: Rev. Infect. Dis.
  doi: 10.1093/clinids/11.Supplement_4.S743
– volume: 360
  start-page: 223
  year: 2018
  ident: ref_98
  article-title: Germinal center antibody mutation trajectories are determined by rapid self/foreign discrimination
  publication-title: Science
  doi: 10.1126/science.aao3859
– volume: 9
  start-page: 4223
  year: 2018
  ident: ref_113
  article-title: Non-neutralizing antibodies elicited by recombinant lassa-rabies vaccine are critical for protection against lassa fever
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-018-06741-w
– volume: 36
  start-page: 4837
  year: 2018
  ident: ref_101
  article-title: Generation of a broadly reactive influenza h1 antigen using a consensus ha sequence
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2018.06.048
– ident: ref_121
  doi: 10.1371/journal.pmed.1002066
– volume: 344
  start-page: 588
  year: 2014
  ident: ref_94
  article-title: Aids/hiv. Host controls of hiv neutralizing antibodies
  publication-title: Science
  doi: 10.1126/science.1254990
– volume: 215
  start-page: 1862
  year: 2017
  ident: ref_74
  article-title: A case of human lassa virus infection with robust acute t-cell activation and long-term virus-specific t-cell responses
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/jix201
– volume: 37
  start-page: 1
  year: 1992
  ident: ref_60
  article-title: Inactivated lassa virus elicits a non protective immune response in rhesus monkeys
  publication-title: J. Med. Virol.
  doi: 10.1002/jmv.1890370102
– volume: 38
  start-page: 407
  year: 1988
  ident: ref_63
  article-title: Viral hemorrhagic fever antibodies in nigerian populations
  publication-title: Am. J. Trop. Med. Hyg.
  doi: 10.4269/ajtmh.1988.38.407
– ident: ref_2
– volume: 35
  start-page: 401
  year: 1986
  ident: ref_24
  article-title: Lassa virus hepatitis: A study of fatal lassa fever in humans
  publication-title: Am. J. Trop. Med. Hyg.
  doi: 10.4269/ajtmh.1986.35.401
– volume: 134
  start-page: 231
  year: 1987
  ident: ref_30
  article-title: Pathophysiology and treatment of lassa fever
  publication-title: Curr. Top. Microbiol. Immunol.
– volume: 41
  start-page: 178
  year: 1995
  ident: ref_116
  article-title: Mhc ligands and peptide motifs: First listing
  publication-title: Immunogenetics
  doi: 10.1007/BF00172063
– volume: 89
  start-page: 2944
  year: 2015
  ident: ref_54
  article-title: The z proteins of pathogenic but not nonpathogenic arenaviruses inhibit rig-i-like receptor-dependent interferon production
  publication-title: J. Virol.
  doi: 10.1128/JVI.03349-14
– volume: 74
  start-page: 2186
  year: 2000
  ident: ref_72
  article-title: Characterization of human CD(+) t-cell clones recognizing conserved and variable epitopes of the lassa virus nucleoprotein
  publication-title: J. Virol.
  doi: 10.1128/JVI.74.5.2186-2192.2000
– volume: 393
  start-page: 705
  year: 1998
  ident: ref_96
  article-title: The antigenic structure of the hiv gp120 envelope glycoprotein
  publication-title: Nature
  doi: 10.1038/31514
– volume: 219
  start-page: 339
  year: 1996
  ident: ref_43
  article-title: When two strands are better than one: The mediators and modulators of the cellular responses to double-stranded rna
  publication-title: Virology
  doi: 10.1006/viro.1996.0259
– volume: 515
  start-page: 138
  year: 2014
  ident: ref_111
  article-title: Broad and potent hiv-1 neutralization by a human antibody that binds the gp41-gp120 interface
  publication-title: Nature
  doi: 10.1038/nature13601
– volume: 80
  start-page: 9192
  year: 2006
  ident: ref_51
  article-title: Inhibition of the type i interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus
  publication-title: J. Virol.
  doi: 10.1128/JVI.00555-06
– volume: 78
  start-page: 3162
  year: 2004
  ident: ref_45
  article-title: Inhibition of different lassa virus strains by alpha and gamma interferons and comparison with a less pathogenic arenavirus
  publication-title: J. Virol.
  doi: 10.1128/JVI.78.6.3162-3169.2004
SSID ssj0000800817
Score 2.152477
SecondaryResourceType review_article
Snippet In 2017, the global Coalition for Epidemic Preparedness (CEPI) declared Lassa virus disease to be one of the world’s foremost biothreats. In January 2018,...
In 2017, the global Coalition for Epidemic Preparedness (CEPI) declared Lassa virus disease to be one of the world's foremost biothreats. In January 2018,...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 84
SubjectTerms Antigens
B cell anergy
broadly-neutralizing antibodies
Chemokines
conformational antigens
conserved antigens
cross-restriction
Cytokines
Dendritic cells
Disease
dominant and subdominant epitopes
Ebola virus
Edema
Epidemics
Fc-gamma receptors
focused immunity
Genetic diversity
Hearing loss
Immune response
Immune system
Infections
Influenza
Interferon
Lassa virus disease (LVD)
Medical research
mimicry
Pathogenesis
Pathogens
Public health
Review
vaccine breadth
Vaccines
Viral diseases
Viruses
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Li9UwFD7IoOBGfFsdJYIbF2XSPJpk6ajDCDKIqMyu5Mm9Iq3c9gru_Bv-PX-JJ22n3DuIbly2SSA5-dJ8pzn5DsAzzoPlTNelCjSWIlhXGmlVSYPRURpX11GMySbU2Zk-PzfvdlJ95ZiwSR54MtyRTUkJm7xnOiK-akeNrqI3IUqdKjbeI0fWs-NMfZ55kK7UdC7J0a_P8dWrDuekVxm2WuztQ6Nc_5845uVQyZ295-Qm3JhJI3kxdfYWXIntbbg2pZH8fgdeLX8GCNI5cow8MAwr0qXx8bTrh18_fvbkTb4KEsn7KSo2kqEjb5E6W_Jpvdn2d-HjyesPL0_LOTtC6aWshzIhdQgxovtWG1uhiYwVXODAk3YUSYIIVQhJWqacRbeK1c77IAxznjLrUsXvwUHbtfEBEIGfrRipdiZxXNA6K8o4laiTPtHKygKOLmzV-Fk6PGew-NKgC5Gt21y2bgHPlxZfJ9mMv9Q9zuZf6mXB6_EFwqCZYdD8CwYFHF5MXjOvwr5h-UyQGSGw-OlSjOsnH4rYNnZbrIONK4PmoQXcn-Z66Qlu74ozpQtQeyjY6-p-SbtejRrdNc-6j_Lh_xjbI7iONG1U4WX6EA6GzTY-hqv-27DuN09G4P8GSsIMTA
  priority: 102
  providerName: Directory of Open Access Journals
Title Improving the Breadth of the Host’s Immune Response to Lassa Virus
URI https://www.ncbi.nlm.nih.gov/pubmed/30373278
https://www.proquest.com/docview/2582829447
https://www.proquest.com/docview/2127198260
https://pubmed.ncbi.nlm.nih.gov/PMC6313495
https://doaj.org/article/aff74afcc28e4256b0981ec9de58f127
Volume 7
WOSCitedRecordID wos000454525400009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2076-0817
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000800817
  issn: 2076-0817
  databaseCode: DOA
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2076-0817
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000800817
  issn: 2076-0817
  databaseCode: M~E
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: Biological Science Database
  customDbUrl:
  eissn: 2076-0817
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000800817
  issn: 2076-0817
  databaseCode: M7P
  dateStart: 20120301
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/biologicalscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 2076-0817
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000800817
  issn: 2076-0817
  databaseCode: BENPR
  dateStart: 20120301
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Publicly Available Content Database
  customDbUrl:
  eissn: 2076-0817
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000800817
  issn: 2076-0817
  databaseCode: PIMPY
  dateStart: 20120301
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bi9QwFD64uwoL4mW9Vdchgi8-lO0lbZIncXSWXdBhWFTGp5KrMyDt7rQj-CL-Df-ev8STtlOdRfbFl0KbBJKc5PTLOSffAXiepkamCc9DZiIbUiNVKDLJwsgIbjOh8tzSNtkEm075fC5mvcGt7sMqNzqxVdSm0t5GfpR4_04iKGUvzy9CnzXKe1f7FBo7sOdZEtI2dG822Fg8GuIx67yTKZ7ufZT1okLJ1MwvXk63_kYtaf-_kOblgMm__kDHt_-373fgVo89yatusdyFa7Y8gBtdNspvB3CzM-GR7mbSPXgzGBwIokQyRnhpmgWpXPt6UtXNrx8_a3Lqb5hYctYF21rSVOQtInJJPi5X6_o-fDievH99EvZJF0KdZXkTOkQkxlo8FeZCxlQ6IWlKcSYdVxFiD2piY1wmE6akH1WutDZUJEpHiVQuTh_AblmV9hEQitrQ2ogr4VLUE9wT1SjmIpVpF8UyC-BoM_mF7hnJfWKMLwWeTLy4isviCuDF0OK8Y-O4ou7Yy3Oo53m02w_V6nPRb8tCOsdwjFon3KL2ylUkeGy1MDbjLk5YAIcbiRb95q6LP-IM4NlQjNvS-1pkaas11sHGscDpiQJ42C2eoSeIGliaMB4A21pWW13dLimXi5b6O089nWT2-OpuPYF9xHUtbW_CD2G3Wa3tU7iuvzbLejWCHTbnI9gbT6azs1FrhBi1-8Y_v0-wZHb6bvbpN5_-JNs
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VAgIJ8SivQAEjwaGHqInzsH1AiFKqXXVZVaig3oKf7EooKZssqDf-Bn-CH8UvYZzsBrZCvfXAMbGd-PF5_I09ngF4liRGJpTnITORDVMjVSgyycLICG4zofLcpm2wCTYe86MjcbAGP5d3YbxZ5VImtoLaVNrvkW9Tf75DRZqyl8dfQh81yp-uLkNodLDYtyffUGWrXwx3cXyfU7r35vD1IFxEFQh1luVN6HDJNdai2pMLGafSCZkmKRInx1WEi2tqYmNcJilT0v8yV1qbVFClIyqVixP87gW4iDSC8tZU8KDf0_Hsi8esOw1NEhF5q-5JhUiomZ8sPF1Z_dogAf9itqcNNP9a8fZu_G99dROuL7g1edVNhluwZssNuNxF2zzZgGvdFiXpbl7dht1-Q4UgCyY7SJ9NMyGVax8HVd38-v6jJkN_g8aSd50xsSVNRUaocUjyYTqb13fg_bk06S6sl1Vp7wNJUdpbG3ElXIJykHtHPIq5SGXaRbHMAtheDnahFx7XfeCPzwVqXh4exWl4BLDVlzjuvI2ckXfH46fP5_2Ety-q2adiIXYK6RzDNmpNuUXpnKtI8NhqYWzGXUxZAJtLBBUL4VUXf-ATwNM-GcWOP0uSpa3mmAcLxwK7JwrgXgfWvibIilhCGQ-ArcB4paqrKeV00ro2zxPvLjN7cHa1nsCVweHbUTEajvcfwlXksK2LYso3Yb2Zze0juKS_NtN69ridnwQ-njfIfwMPtHwX
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6V8hAS4lFegQJGggOHaBPHie0DQpRl1VXLaoUA9RYcP-hKaFM2WVBv_A3-Cj-HX8I4yQa2Qr31wDGxnfjxeR6e8QzAkyQxKqEiC7mJbMiMKkKZKh5GRgqbyiLLLGuSTfDJRBwcyOkG_FzdhfFulSua2BBqU2p_Rj6g3r5DJWN84Dq3iOlw9OLoS-gzSHlL6yqdRguRPXv8DdW36vl4iGv9lNLR63evdsMuw0Co0zSrQ4fs11iLKlAmVcyUk4olDIUoJ4oIGS0zsTEuVZQXyv8-K7Q2TNJCR1QVLk7wu-fgPGdZQxTe8Gl_vuMlMRHz1jKaJDLyHt6HJaKi4n7jCLbGCZuEAf-Sck86a_7F_UbX_ud5uw5XO5mbvGw3yQ3YsPMtuNhm4Tzegivt0SVpb2TdhGF_0EJQOiY7KFab-pCUrnncLav61_cfFRn7mzWWvG2djC2pS7KPmogiH2aLZXUL3p_JkG7D5ryc27tAGHIBayNRSJcgfRQ-QE_BXVSk2kWxSgMYrBY-110kdp8Q5HOOGpmHSn4SKgE861sctVFITqm747HU1_Pxw5sX5eJT3pGjXDnHcYxaU2GRamdFJEVstTQ2FS6mPIDtFZryjqhV-R8oBfC4L0Zy5G1Mam7LJdbBxrHE6YkCuNMCt-8JSks8oVwEwNcgvdbV9ZL57LAJeZ4lPoxmeu_0bj2CS4jtfH882bsPl1G0bSIXU7ENm_ViaR_ABf21nlWLh81WJfDxrDH-G-EthNU
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Improving+the+Breadth+of+the+Host%E2%80%99s+Immune+Response+to+Lassa+Virus&rft.jtitle=Pathogens+%28Basel%29&rft.au=Zapata%2C+Juan+Carlos&rft.au=Medina-Moreno%2C+Sandra&rft.au=Guzm%C3%A1n-Cardozo%2C+Camila&rft.au=Salvato%2C+Maria+S&rft.date=2018-10-28&rft.pub=MDPI+AG&rft.eissn=2076-0817&rft.volume=7&rft.issue=4&rft.spage=84&rft_id=info:doi/10.3390%2Fpathogens7040084&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2076-0817&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2076-0817&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2076-0817&client=summon